## **Core Evidence**

#### Open Access Full Text Article

### CORRIGENDUM

# Development of cabozantinib for the treatment of prostate cancer [Corrigendum]

Vaishampayan UN. Core Evidence. 2014;9:61-67.

On page 62, line 6 of the Introduction section and page 67, line 2 of the Disclosure statement, "Exelexis Inc." should read "Exelixis Inc.".

### Core Evidence

### Publish your work in this journal

Core Evidence is an international, peer-reviewed open-access journal evaluating the evidence underlying the potential place in therapy of drugs throughout their development lifecycle from preclinical to postlaunch. The focus of each review is to evaluate the case for a new drug or class in outcome terms in specific indications and patient groups.

Submit your manuscript here: http://www.dovepress.com/core-evidence-journal

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

submit your manuscript | www.dovepress.com
Dovepress

http://dx.doi.org/10.2147/CE.S67095

Core Evidence 2014:9 69

© 2014 Yaishampayan. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution — Non Commercial (unported, v3.0) permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited, Information on how to request permission may be found at http://www.dovepress.com/permissions.pbp

69

**Dove**press